Memantine combined with an acetyl cholinesterase inhibitor - Hope for the future?

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 2, 2006, Pages 121-125

  Fox, Chris ^a,c   Maidment, Ian D ^a   Boustani, Malaz ^b   Katona, Cornelius ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

^b INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^c Folkstone Health Centre   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Combination; Memantine; Open label studies; Randomised control studies

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PLACEBO;

ADD ON THERAPY; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFUSION; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FUNCTIONAL STATUS; HEADACHE; HUMAN; MONOTHERAPY; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SYSTEMATIC REVIEW;

EID: 33745910537     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.2.121     Document Type: Note

References (37)

1. [AD2000] AD2000 Collaborative Group. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet, 363:2105-15.
2. [APA] American Psychiatric Association 1994. Diagnostic and statistical manual of mental disorders. 4th ed (DSM-IV). Washington DC: APA.
3. Bandolier. Adverse nondrug reactions [online]. Accessed 20 Sept 2003. URL: http://www.jr2.ox.ac.uk/bandolier/band115/b115-4.html.
4. Bartus RT, Dean RL, Beer B, et al. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science, 217:408-17.
5. Becker RE. 1991. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In Becker RE, Giacobini E (eds). Cholinergic basis for Alzheimer therapy. Boston: Birkhauser.
6. Boustani M, Peterson B, Hanson L, et al. Screening for dementia. systematic evidence review [online]. Rockville, MD: Agency for Healthcare Research and Quality. Accessed 23 Sept 2003. URL: http://www.ahrq.gov/clinic/uspstfix.htm.
7. Cohen J. 1988. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Erlbaum.
8. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44:2308-14.
9. Doody R, Tariot PN, Pfeiffer E, et al. 2005. Metanalysis of 6-month memantine clinical trials in Alzheimer's disease [abstract] [online]. New Clinical Drug Evaluation Unit 45th Annual General Meeting. 2005 June 6-9; FL, USA. Accessed 14 Dec 2005. URL: http://www.nimh.nih.gov/ncdeu/ posterabstracts.cfm.
10. Folstein MF, Folstein SE, McHugh PR. 1975. Mini-mental state: a practical method for grading the mental state of patients for the clinician. J Psychiatr Res, 12:189-98.
11. [FLI] Forest Laboratories Inc. 2003. Combined therapy of memantine and acetylcholinesterase inhibitors for the treatment of mild to moderate Alzheimer's disease did not demonstrate statistically significant effects on cognitive or global outcome compared to placebo/ acetylcholinesterase treat. [Press release available online]. Accessed 25 July 2005. URL: http://www.frx.com.
12. [FDA] Food and Drug Administration 2005. Mild Alzheimer's disease licence extension rejection [announcement]. 2005 Aug 5.
13. Francis PT. 2003. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry, 18:S15-21.
14. Fox GC, Boustani M, Edwards C. 2003. Good practice in appraising trials. International Guideline and Approaches. Int Psychogeriatr, 15(Suppl 2):S27.
15. Galasko DR., Bennett D, Sano M et al. 1997. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzh Dis Assoc Disord, 11:S33-9.
16. Giacobini E. 2004. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res, 50:433-40.
17. Hartmann S, Mobius SJ 2003. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clinical Psychopharmacology, 18: 81-5.
18. Khan KS, Riet GT, Popoay J, et al. 2001. Stage 11 conducting the review phase 5 study quality assessment York Centre for Reviews and Dissemination. York: York Publishing Services Ltd, NHS Centre for reviews and dissemination, University of York.
19. Kukull WA, Bowen JD. 2002. Dementia epidemiology. Med Clin North Am, 86:573-90.
20. Lane RM, Kivipelto M, Greig N. 2004. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol, 27:141-9.
21. Lexchin J, Bero LA, Djulbegovic B, et al. 2003. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ, 326:1167.
22. Maidment I, Fox C, Livingston G, et al. 2006. Drug treatment for Alzheimer's disease: the way forward. Int J Geriatr Psychiatry, 21: 6-8.
23. National Institute for Clinical Excellence. Donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease [online]. Accessed 23 January 2006. URL: http://www.nice.org.uk/article.asp?a=14487.
24. Panisset M, Roudier M, Saxton J, et al. 1994. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol, 51:41-5.
25. Pass MD, Shua-Haim JR, Patel P, et al. 2004. Tolerability and caregiver's impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer's disease [abstract]. Neurobiol Aging, 25(Suppl):S210.
26. Patel S, Shua-Haim JR, Pass MD, Lee P. 2004. Safety, tolerability and caregiver's impressions of combination therapy with donepezil and memantine for the treatment of Alzheimer's disease [abstract]. Neurobiol Aging, 25(Suppl):S204-5.
27. Reisberg B, Doody R, Stoffler A, et al. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 348(14):1333-41.
28. Rockwood K. 2004. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 75:1086.
29. Samochocki M, Zerlin M, Jostock R, et al. 2000. Galantamine is an allosterically potentiating ligand of the human alpha 4/beta 2 nAChR. Acta Neurol Scand, 176(Suppl):S68-73.
30. Schneider LS, Olin JT, Doody RS, et al 1997. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Dis Assoc Disord, 11:S22-32.
31. Schneider J, Murray J, Banerjee S, et al. 1999. EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I-Factors associated with carer burden. Int J Geriatr Psychiatry, 14:651-61
32. Shua-Haim JR, Pass MD, Patel S, et al. 2004. Safety, tolerability and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease [abstract]. Neurobiol Aging, 25(Suppl):S205.
33. Sloane PD, Zimmerman S, Suchindran B. 2002. Impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health, 23:213-31.
34. Tariot PN, Farlow MR, Grossberg GT, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - a randomized controlled trial. JAMA, 291:317-24.
35. van der Kam P, Mol F, Wimmers M. 1971. Beoordelingsschaal voor Oudere Patienten (BOP). Deventer, The Netherlands: Van Loghum Slaterus.
36. Wenk GL, Quack G, Moebius HJ, et al. 2000. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci, 66:1079-83.
37. Yamada K, Takayanagi M, Kamei H, et al. 2005. Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res, 162: 191-9.